Portfoliotracker

Kura Oncology, Inc.

KURA · NASDAQGS · Healthcare Biotechnology 0/100 E

7,290 $
▲ +0,200 (+2,82 %)
Trading delayed by 15 min
Price as of 17. 11. 17:28, fetched 17. 11. 17:29
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score0 / 100 Market cap637 mil. $ P/E– Forward P/E-2,9 P/S8,0 P/B35,5 EV/EBITDA– Dividend yield– FCF yield-14,00 % EPS-3,45 $ Net margin0,0 % Return on equity-224,9 % Beta0,53 Debt / equity1,44
52-week range 6,75 to 13,90
3-month average volume2,1 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Employees
260
Country
United States
Fiscal year end
31. 12.
Data since
16. 9. 2015

Explore further

Similar companies SNDXANABRGNXREPLXNCR

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account